{"id":868145,"date":"2025-07-09T19:38:52","date_gmt":"2025-07-09T23:38:52","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/"},"modified":"2025-07-09T19:38:52","modified_gmt":"2025-07-09T23:38:52","slug":"spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/","title":{"rendered":"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering"},"content":{"rendered":"<div class=\"mw_release\">\n<p>New York, NY, July  09, 2025  (GLOBE NEWSWIRE) &#8212; Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.<\/p>\n<p>Lixte Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company focused on cancer drug development, completed the offering on July 8, 2025. The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-Funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54, and $1.53999 per Pre-Funded Warrant, which includes an exercise price of $0.00001.<\/p>\n<p>The Company received gross proceeds of approximately $1.5 million. The net proceeds, together with the Company\u2019s existing cash, will be used for general corporate purposes and working capital.<\/p>\n<p>\n        <strong>\u201cThis transaction reflects our continued focus on aligning innovative biotech companies with the strategic capital they need to advance breakthrough therapies,\u201d<\/strong> said John Lowry, CEO of Spartan Capital Securities. <strong>\u201cWe are pleased to support Lixte Biotechnology Holdings, LLC in this important stage of their clinical development and look forward to seeing the impact of their work in the oncology space<\/strong>.\u201d<\/p>\n<p>Lixte was represented by TroyGould PC, while Spartan Capital Securities was represented by Kaufman &amp; Canoles, P.C.<\/p>\n<p>The offering was made pursuant to an effective shelf registration statement on Form S-3 (No. 333-278874) previously filed with and declared effective by the U.S. Securities and Exchange Commission on May 2, 2024. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bJHa0EqVAVIUXDy5DpwbawcxbZZvLUnPrYr49K3wTg7QLMgsta90zvy8FFKqykjhkP14YyZDooqOlOiWRBklQA==\" rel=\"nofollow\" target=\"_blank\">www.sec.gov<\/a>.<\/p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.<\/p>\n<p>\n        <strong>About Spartan Capital Securities, LLC<br \/><\/strong>Spartan Capital Securities, LLC is a premier full-service investment banking firm offering a comprehensive range of advisory services to institutional clients and high-net-worth individuals. Known for its expertise in capital raising, strategic advisory, and asset management, Spartan Capital delivers tailored solutions to meet clients\u2019 financial goals.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bJHa0EqVAVIUXDy5Dpwba5O57Nq5jGDwYimKQVPEXPpHV_yEeaH8FV8dEhGucHAZA6jzhnyx86kzGND0FYTxqCjaOx4LERweNhhavDyW954=\" rel=\"nofollow\" target=\"_blank\">www.spartancapital.com<\/a>.<\/p>\n<p>\n        <strong>About Lixte Biotechnology Holdings, Inc.<br \/><\/strong>Lixte Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on discovering and developing cancer therapies based on novel biological pathways. Its lead compound, LB-100, a first-in-class PP2A inhibitor, has shown promise in enhancing the effectiveness of chemotherapy and immunotherapy. Clinical trials are currently underway for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma.<\/p>\n<p>For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S53GRmKIQWkTXq58vTS4YeOeBCqIM3zxkZdrMWBo61K6XCiyZ9xiGvUEQeHpKOmTsIml5ziyjibdbrV4mE7yHA==\" rel=\"nofollow\" target=\"_blank\">www.lixte.com<\/a>.<\/p>\n<p>\n        <strong>Contact:<br \/><\/strong>Spartan Capital Securities, LLC<br \/>45 Broadway, 19th Floor<br \/>New York, NY 10006<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DrbX42tqWqm1YeQzMCbYXjhvz4m5xpowudmvH9pjiuxl8idgWZ8-qoNwaUeUnSXvCsUUMkA1De0aVX8t94dumwhwnYTRa6a3mPwEEfj0xcAs6uPjBDN7uVhBw-xEevpx4bHcoBJ_AWwtJ4tOydlT3w==\" rel=\"nofollow\" target=\"_blank\">investmentbanking@spartancapital.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MGY3NDY3OTQtZGFlNC00MjRhLWFlNTUtNGM1NWJiYjM5N2Q5LTUwMDEyMzQzOC0yMDI1LTA3LTA5LWVu\/tiny\/Spartan-Capital-Securities-LLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>New York, NY, July 09, 2025 (GLOBE NEWSWIRE) &#8212; Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent. Lixte Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company focused on cancer drug development, completed the offering on July 8, 2025. The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-Funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54, and $1.53999 per Pre-Funded Warrant, which includes an exercise price of $0.00001. The Company received gross proceeds of approximately $1.5 million. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-868145","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"New York, NY, July 09, 2025 (GLOBE NEWSWIRE) &#8212; Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent. Lixte Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company focused on cancer drug development, completed the offering on July 8, 2025. The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-Funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54, and $1.53999 per Pre-Funded Warrant, which includes an exercise price of $0.00001. The Company received gross proceeds of approximately $1.5 million. &hellip; Continue reading &quot;Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T23:38:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering\",\"datePublished\":\"2025-07-09T23:38:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/\"},\"wordCount\":480,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/\",\"name\":\"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==\",\"datePublished\":\"2025-07-09T23:38:52+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/","og_locale":"en_US","og_type":"article","og_title":"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering - Market Newsdesk","og_description":"New York, NY, July 09, 2025 (GLOBE NEWSWIRE) &#8212; Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent. Lixte Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company focused on cancer drug development, completed the offering on July 8, 2025. The offering consisted of the sale of an aggregate of 974,026 shares of Common Stock (or Pre-Funded Warrants in lieu thereof). The public offering price per share of Common Stock was $1.54, and $1.53999 per Pre-Funded Warrant, which includes an exercise price of $0.00001. The Company received gross proceeds of approximately $1.5 million. &hellip; Continue reading \"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-09T23:38:52+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering","datePublished":"2025-07-09T23:38:52+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/"},"wordCount":480,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/","name":"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==","datePublished":"2025-07-09T23:38:52+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ5MTk4MCM3MDQwNjQzIzUwMDEyMzQzOA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/spartan-capital-securities-llc-serves-as-placement-agent-in-lixte-biotechnology-holdings-inc-s-1-5-million-registered-direct-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.\u2019s $1.5 Million Registered Direct Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=868145"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/868145\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=868145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=868145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=868145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}